ContractClinical Batch Development and Production Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
SUBSCRIPTION AGREEMENT By and between Abivax S.A. as Issuer and Kreos Capital VII (UK) Limited Kreos Capital VII Aggregator SCSp Claret European Specialty Lending Company III, S.à r.l. Claret European Growth Capital Fund III SCSp As SubscribersSubscription Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
This subscription agreement (hereinafter referred to as the “Subscription Agreement”) is entered into on 20 August 2023, by and between:
ContractDrug Discovery Services Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractManufacturing Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractLoan Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractAmendment N°1 • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
ContractLoan Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
⚫ ] Ordinary Shares and [ ⚫ ] American Depositary Shares, Each Representing One Ordinary Share (Nominal Value €0.01 per Share) ABIVAX SA UNDERWRITING AGREEMENTUnderwriting Agreement • October 18th, 2023 • Abivax S.A. • Pharmaceutical preparations • New York
Contract1st Amendment to Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractFinancial Terms Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractIntellectual Property Rights Pledge Deed • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
MASTER SERVICES AGREEMENTMaster Services Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
This Master Services Agreement (“Agreement”) effective as of 17th December, 2018 (“Effective Date”) is made between ABIVAX SA which has a place of business at 5, rue de la Baume—F-75008 Paris—France (“Sponsor”) and IQVIA Ltd of 500 Brook Drive, Green Park, Reading, Berkshire RG2 6UU (“IQVIA”). When signed by both parties, this Agreement will set forth the terms and conditions under which IQVIA agrees to provide certain services to Sponsor as set forth herein.
Dated 20 August 2023 Subscription Agreement €35,000,000 Amortizing Senior Notes Convertible into New Shares of Abivax due 2027 (the “Tranche A Notes”) and Up to €40,000,000 Amortizing Senior Notes Convertible into New Shares of Abivax (the “Tranche(s)...Subscription Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
ContractTranche a-B Warrants Issue Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
ContractCollaboration Agreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractAgreement • September 29th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential.
ContractOcabsa Issue Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.
TRANCHE A-B PUT OPTION AGREEMENT BSA2023-KC-AB By and between Abivax S.A. as Issuer and Kreos Capital VII Aggregator SCSp Claret European Growth Capital Fund III SCSp as BeneficiariesPut Option Agreement • September 8th, 2023 • Abivax S.A. • Pharmaceutical preparations
